Join
Live feed
·
PRReleasevia Quantisnow
Q32 Bio Inc. logo

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

ByQuantisnow·Wall Street's wire, on your screen.
QTTB· Q32 Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QTTB (Q32 Bio Inc.) and more on Quantisnow.